About Innovita Biological Technology Company

The company is a high-tech biomedical enterprise focusing on R&D, production and sales of POCT rapid diagnostic products. It was listed on the Science and Technology Innovation Board on July 28, 2022. The company is characterized by respiratory pathogen testing and joint testing for various pathogens. It uses emergency outpatient care, especially emergency outpatient testing for children, as an entry point, and is committed to building a leading brand for rapid joint testing of respiratory pathogens in China. The company is a high-tech biomedical enterprise focusing on R&D, production and sales of POCT rapid diagnostic products. The company's main products: full blood breathing 5-item test kit; influenza antigen triple-test kit; influenza antibody triple-test kit; serum respiratory 5-item test kit; respiratory fluorescence 9-item test kit; novel coronavirus IgM/IgG antibody test kit; novel coronavirus antigen test kit; intestinal antigen trifecta test kit; eugenics series test products; influenza A virus, influenza B virus, novel coronavirus antigen combined test kit; parainfluenza virus and adenovirus antigen combined test kit; combined test kit for parainfluenza virus and adenovirus antigen influenza virus, influenza B virus, respiratory tract Syncytial virus and metapulmonary virus antigen combined test kit; Mycoplasma pneumoniae and Chlamydia pneumoniae IgM combined test kit; malaria antigen rapid test kit; dengue virus rapid test kit, etc.